VISEN Pharmaceuticals
Company Profile
Business description
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
Contact
69 Jiuzhang Road
Suite 3-108, Floor 3, Building B
Hengtai Lixiang Chuangxin Tower
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
54
Stocks News & Analysis
stocks
Alibaba fair value increases by 49%
stocks
A 5-Star US stock to buy with a near-5% yield
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,148.50 | 45.40 | 0.50% |
CAC 40 | 7,883.96 | 13.28 | 0.17% |
DAX 40 | 23,743.27 | 3.80 | 0.02% |
Dow JONES (US) | 46,247.29 | 299.97 | 0.65% |
FTSE 100 | 9,337.90 | 53.07 | 0.57% |
HKSE | 26,622.88 | 494.68 | 1.89% |
NASDAQ | 22,484.07 | 99.37 | 0.44% |
Nikkei 225 | 45,043.75 | 311.24 | -0.69% |
NZX 50 Index | 13,132.56 | 20.83 | 0.16% |
S&P 500 | 6,643.70 | 38.98 | 0.59% |
S&P/ASX 200 | 8,862.80 | 52.10 | 0.59% |
SSE Composite Index | 3,862.53 | 34.43 | 0.90% |